´ëÇÑ°ñ´ë»çÇÐȸ È£³²Áöȸ Á¦1Â÷ Çмú´ëȸ ¹× Á¦4Â÷ °ñ´Ù°øÁõ °³¿øÀÇ ¿¬¼ö°Á : 2019-11-30±³À°ÀÏÀÚ : 2019-11-30
±³À°Àå¼Ò : ÀüºÏ´ëÇб³º´¿ø Àӻ󿬱¸Áö¿ø¼¾ÅÍ 2Ãþ »õ¸¸±ÝȦ (¿¬¼ö°ÁÂ) / 1Ãþ ȸÀÇ½Ç (Çмú´ëȸ)
±³À°ÁÖÁ¦ :
´ëÇÑ°ñ´ë»çÇÐȸ È£³²Áöȸ Á¦1Â÷ Çмú´ëȸ ¹× Á¦4Â÷ °ñ´Ù°øÁõ °³¿øÀÇ ¿¬¼ö°ÁÂÁÖÃÖ±â°ü : ´ëÇÑ°ñ´ë»çÇÐȸ
´ã´çÀÚ : ÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3473-2230
À̸ÞÀÏ :
bone90@empal.com ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, »ê¾÷ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¹ýÀÇÇÐ, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
Àü¶óºÏµµ±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-30 Çмú´ëȸ ȸÀÇ½Ç 12:30~13:50 µî·Ï ()
±âŸ 11-30 Çмú´ëȸ ȸÀÇ½Ç 13:50~14:00 °³È¸»ç Á¤µ¿Áø(È£³²Áöȸ ȸÀå)
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 14:00~14:20 The role of Src and Cbl during Osteoblast Differentiation À̱¤¿(Àü³²´ë ¾àÇдëÇÐ)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 14:20~14:25 Q & A ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 14:25~14:45 The role of Hypoxia-inducible factor-2a 12in bone homeostasis ·ùÁ¦È²(Àü³²´ë Ä¡ÀÇÀü)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 14:45~14:50 Q & A ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 14:50~15:10 Avascular necrosis of the bone and Sirt 6 ¹®¿µÀç(ÀüºÏÀÇ´ë Á¤Çü¿Ü°ú)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 15:10~15:15 Q & A ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 15:15~15:35 Computational modeling in cellular signaling research ÇÏ»óÈÆ(ÀüºÏ´ë »ý¸í°øÇкÎ)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 15:35~15:45 Q & A ()
ÈÞ½Ä 11-30 Çмú´ëȸ ȸÀÇ½Ç 15:45~16:00 Coffee break ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:00~16:10 Effect of GLP-1 agonist on osteoblast Jin Hong Chen(ÀüºÏÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:10~16:15 Q & A ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:15~16:25 Cuedc2 negatively regulates bone formation through inhibiting Stat3 phosphorylation ±èÁ¤¿ì(Àü³²´ë Ä¡ÀÇÀü)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:25~16:30 Q & A ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:30~16:40 Potential roles of DEC-1 in interconnecting circadian rhythm and osteoarthritis ¹Ú°¡Çö(Àü³²´ë Ä¡ÀÇÀü)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:40~16:45 Q & A ()
±³À°½Ã°£ 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:45~16:55 STAT5 negatively regulates bone marrow mesenchymal stem cell-derived adipocyte differentiation via ATF3 ¼º¼¼¹®(Àü³²ÀÇ´ë ¾à¸®Çб³½Ç)
Åä·Ð 11-30 Çмú´ëȸ ȸÀÇ½Ç 16:55~17:00 Q & A ()
±âŸ 11-30 Çмú´ëȸ ȸÀÇ½Ç 17:00~17:05 Æóȸ»ç ()
±âŸ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 12:30~13:30 µî·Ï ()
±âŸ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 13:30~13:35 °³È¸»ç Á¤µ¿Áø(È£³²Áöȸ ȸÀå)
±âŸ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 13:35~13:40 Ãà»ç Á¤È£¿¬(°ñ´ë»çÇÐȸ ÀÌ»çÀå)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 13:40~14:00 Ä®½·¿Ü »À¿¡ Áß¿äÇÑ Çʼö¿µ¾ç¼Ò ¼·Ã븦 À§ÇÑ ½ÄÀÌ¿ä¹ý ¹Ú¿ëÁÖ(Àü³²´ë ½ÄÇ°¿µ¾ç°úÇкÎ)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 14:00~14:20 »À¸¦ À§ÇÑ ºñŸ¹Î D Ä¡·áÀÇ ÀûÀÀÁõ ¹× Åõ¿©¹ý (optimal regimen) È«ÁØÈ(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 14:20~14:40 °ñ°¨¼ÒÁõ(Osteopenia) ȯÀÚÀÇ Ä¡·á ¹× ÃßÀû°ü¸® Á¶¹®°æ(Àü³²ÀÇ´ë »êºÎÀΰú)
Åä·Ð 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 14:40~14:55 Q & A ()
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 14:55~15:15 ¼Õ¸ñ °ñÀýÀÇ À§Ç豺 ¹× ¿¹¹æ°ú Ä¡·á ¹ÚÈ£¿¬(°¡Å縯ÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 15:15~15:35 ôÃß °ñÀýÀÇ Ä¡·á ÀûÀÀÁõ ±è¼º±Ô(Àü³²ÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 15:35~15:55 ´ëÅð°ñ °ñÀýÀÇ »ý¿ªÇÐ ¹× Ä¡·á À±¼±Áß(ÀüºÏÀÇ´ë Á¤Çü¿Ü°ú)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 15:55~16:15 Ãë¾à °ñÀýÀÇ ±¹°¡ °ü¸® Á¦µµ ¼Ò°³ : Fracture Liaison Service (FLS) Â÷¿ëÇÑ(À»ÁöÀÇ´ë Á¤Çü¿Ü°ú)
Åä·Ð 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 16:15~16:35 Q & A ()
ÈÞ½Ä 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 16:35~16:50 Coffee break ()
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 16:50~17:10 °ñ´Ù°øÁõ 1Â÷ ¾àÁ¦ ¼±Åà (Bisphosphonate vs. Denosumab vs. Teriparatide) ¹«¾ùÀ» ±âÁØÀ¸·Î ÇÒ°ÍÀΰ¡? ±èºÎ°æ(°í½ÅÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 17:10~17:30 °ñ´Ù°øÁõ Ä¡·áÀÇ Àå±â°èȹ: È¿°úÀû ¼øÂ÷¿ä¹ý (Sequential therapy) ±¸À¯Á¤(ÃæºÏÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 17:30~17:50 °ñ´Ù°øÁõ ½Å¾à: Romosozumab ±âÀü°ú Ä¡·á ÃÖ¿ëÁØ(¾ÆÁÖÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 17:50~18:05 Q & A ()
±âŸ 11-30 ¿¬¼ö°Á »õ¸¸±ÝȦ 18:05~18:10 Æóȸ»ç ()